Rachel Narozniak, MA

Therapeutic options for pretreated HER2-positive breast cancer now include tucatinib (Tukysa) as part of a triplet regimen with a tolerable safety profile that promises improved quality of life.

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

In an era of value-based care, the ability to triage the needs of patients with cancer who are most likely to experience significant difficulties is becoming a priority for community oncology practices and hospital systems.

The American Society of Clinical Oncology and College of American Pathologists have further refined their recommendations for estrogen receptor and progesterone receptor testing protocols in patients with breast cancer.

Hoping to minimize the off-target effects associated with radiation in patients with oropharyngeal cancer, investigators are testing the hypothesis that intensitymodulated proton therapy can deliver doses as effectively as the current standard of care with less damage to surrounding tissue.

With travel restrictions and reduced transportation options, the global spread of coronavirus disease 2019 has disrupted international networks that supply patients with biological materials needed for sophisticated hematologic therapies.

ECOG performance status, cancer type, and type of prior therapy received can predict risk for clinical worsening or death in patients with cancer who contract the coronavirus disease 2019.

Investigators are testing the hypothesis that administering cetuximab with an anti–PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma.

Adam M. Brufsky, MD, PhD, FACP, discusses the use of neratinib and the importance of expanding the treatment portfolio in HER2-positive metastatic breast cancer.

When the first case of coronavirus disease 2019 was diagnosed in Washington on January 20, 2020 clinicians at Seattle Cancer Care Alliance decided to act expeditiously and unhesitatingly to minimize disease spread.

From implementing telemedical approaches to resequencing treatments, cancer centers across the nation have nimbly adapted to face the clinical challenges posed by the novel coronavirus 2019 disease.

Motivated to move the needle in cervical cancer, investigators are adding durvalumab to standard-of-care concurrent chemoradiation therapy and brachytherapy to determine whether PD-L1 blockade is a key to improving survival outcomes.

Ken Shain, MD, PhD, discusses isatuximab-irfc and its potential to move into different stages of the multiple myeloma paradigm following further clinical investigation.

The need to establish preventive procedures that keep pace with the rapid evolution of coronavirus 2019 presents numerous challenges for the oncology field as institutions adapt standard treatment protocols to minimize the risk for virus spread among clinicians and patients alike.

Investigators are evaluating whether the addition of venetoclax to a standard doublet regimen in chronic lymphocytic leukemia can induce responses deep enough to allow patients to not only suspend long-term treatment but also avoid associated toxicity.

Michael C. Heinrich, MD, discusses the recent approval of avapritinib for advanced PDGFRA exon 18–mutated gastrointestinal stromal tumor.

In metastatic urothelial cancer, the portfolio of immunologic therapies is robust, but the treatment paradigm for these agents requires refinement.

Driven by advances in genetic testing methods and the discovery of actionable mutations beyond BRCA, an update to the National Comprehensive Cancer Network’s Guidelines for genetic testing in breast, ovarian, and pancreatic cancers encompasses a much broader range of genes that predict risk for disease occurrence.

Patient concern about coronavirus 2019 varies by oncology clinic according to the OncologyLive® advisory board members, who discussed in a recent interview how COVID-19 has guided their patient interactions and what steps they are advising patients to take to protect themselves.

Investigators propose that a PI3K-δ,γ inhibitor currently indicated for the treatment of 3 hematologic malignancies may be a key to boosting response rates in peripheral T-cell lymphoma, a disease setting defined by poor prognoses.

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Patients with preexisting inflammatory bowel disease have a significantly higher risk of developing gastrointestinal adverse events during treatment with an immunotherapybased anticancer regimen than those without inflammatory bowel disease.

Infectious diseases are the second-leading cause of mortality in patients with cancer, whose immune systems are often compromised, so it is essential for providers to keep abreast of the latest developments in the management of coronavirus disease 2019.

The approval of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers, according to a panel of experts in gastrointestinal malignancies.

Investigators will challenge therapeutic convention by testing a PARP inhibitor instead of an IDH-targeted therapy in patients with metastatic IDH1/2-mutated glioma, cholangiocarcinoma, and other solid tumors that are refractory to standard treatment.

In response to a rise in hematopoietic cell transplantation, the National Comprehensive Cancer Network has published its first guideline for the specialized intervention, which is performed approximately 22,000 times a year in the United States in patients with hematological cancers and other diseases.

Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care for patients with advanced or metastatic treatment-naïve RET fusion–positive non–small cell lung cancer in the phase III LIBRETTO-431 (NCT04194944) trial.

Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual International Congress on Immunotherapies in Cancer®. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.